Information Provided By:
Fly News Breaks for December 10, 2019
SNY, THOR
Dec 10, 2019 | 07:05 EDT
H.C. Wainwright analyst Debjit Chattopadhyay downgraded Synthorx (THOR) to Neutral from Buy with a price target of $68, up from $30. The analyst cites the takeover by Sanofi (SNY) for the downgrade.
News For THOR;SNY From the Last 2 Days
SNY
Mar 27, 2024 | 06:16 EDT
Wells Fargo analyst Derek Archila raised the firm's price target on Annexon (ANNX) to $12 from $11 and keeps an Overweight rating on the shares. The firm believes the risk/reward remains favorable ahead of ANX005's Phase 3 data in GBS. Additionally, updates for ANX007 at ARVO, Phase 3 GBS data at PNS and read through from Sanofi's (SNY's) riliprubart in CIDP at AAN, all could offer upside for shares, Wells adds.